Edwards Lifesciences' EVOQUE System Demonstrates Sustained Patient Benefits

Two-year data shows significant improvements for patients with tricuspid valve disease.

Mar. 30, 2026 at 6:08pm

Got story updates? Submit your updates here. ›

Edwards Lifesciences, a leading medical device company, has announced new data on its EVOQUE transcatheter tricuspid valve replacement (TTVR) system. The data, presented at the American College of Cardiology's Annual Scientific Session, shows significant and sustained patient benefits over a two-year period for those with tricuspid valve disease.

Why it matters

Tricuspid valve disease is a complex and challenging condition that can lead to serious health complications if left untreated. The EVOQUE system represents a promising new treatment option that could improve outcomes for patients suffering from this condition.

The details

The EVOQUE system is a minimally invasive transcatheter valve replacement procedure that allows doctors to replace a patient's diseased tricuspid valve without open-heart surgery. The new data presented shows that patients who underwent the EVOQUE procedure experienced significant improvements in functional status, quality of life, and other key clinical measures over a two-year follow-up period.

  • The data was presented at the American College of Cardiology's Annual Scientific Session in March 2026.

The players

Edwards Lifesciences

A leading medical device company that develops innovative solutions for structural heart disease, including the EVOQUE transcatheter tricuspid valve replacement system.

EVOQUE Transcatheter Tricuspid Valve Replacement (TTVR) System

A minimally invasive valve replacement procedure developed by Edwards Lifesciences to treat patients with tricuspid valve disease.

Got photos? Submit your photos here. ›

What they’re saying

“These two-year results demonstrate the sustained clinical benefits of the EVOQUE system for patients with severe tricuspid regurgitation, an underserved and complex patient population.”

— Bernard Zovighian, Corporate Vice President, Transcatheter Mitral and Tricuspid Therapies at Edwards Lifesciences

What’s next

Edwards Lifesciences plans to continue studying the long-term performance and safety of the EVOQUE system through ongoing clinical trials and post-market surveillance.

The takeaway

The promising results from the EVOQUE system demonstrate the potential for innovative transcatheter therapies to improve outcomes for patients with complex structural heart conditions like tricuspid valve disease, where treatment options have historically been limited.